Thiocarbonyl photosensitizer, a feasible way to eliminate the photosensitizer residues in photodynamic therapy

Spectrochim Acta A Mol Biomol Spectrosc. 2022 Apr 5:270:120783. doi: 10.1016/j.saa.2021.120783. Epub 2021 Dec 28.

Abstract

Photodynamic therapy (PDT) has been successfully applied in clinical treatment several years. However, after finished treatment process the residual photosensitizer will spread throughout body, which forces patients stay in the dark room to avoid exposure in sunlight several weeks. Therefore, develop degradable photosensitizer could effectively eliminate this inconvenience. In the past, researchers have developed degradable photosensitizers based on supramolecular structure. In this study, we achieved the same effect in small molecule level. Three thiocarbonyl photosensitizers (PS) have high photogenerated 1O2 quantum yield and can be photodegraded by laser irradiation within 15 min. And due to its high phototoxicity and low toxicity, thiocarbonyl PS still maintains its high phototoxicity. Especially, mitochondrial targeting PS 1a has better properties than many BODIPY or cyanine heavy-atom-free photosensitizers. It only needs 1 μM to reduce HeLa cell activity to 30%. Finally the thiocarbonyl PS provided a convenient way to solve the PS residue problem without sacrificing PDT efficiency.

Keywords: Heavy-atom-free photosensitizers; Inter system crossing (ISC); Photodynamics therapy (PDT); Thiocarbonyl photooxidation.

MeSH terms

  • Coloring Agents
  • HeLa Cells
  • Humans
  • Photochemotherapy*
  • Photosensitizing Agents* / therapeutic use

Substances

  • Coloring Agents
  • Photosensitizing Agents